Bioxytran, Inc. ($BIXT) is a game-changer in the treatment of hypoxia, a condition with dire consequences if not addressed promptly. Their clinical-stage pharmaceutical developments offer a glimmer of hope for patients worldwide. With a market cap of $26,866,136 and 137,775,058 outstanding shares on the OTC market